Recent advances in controlled pulmonary drug delivery

Drug Discovery Today

Volumn 20, Issue 3, 2015, Pages 380-389

  Liang, Zhenglin ^a   Ni, Rui ^a   Zhou, Jieyu ^a   Mao, Shirui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; DEOXYCHOLATE SODIUM; LIPOSOME; MICROSPHERE; NANOCARRIER; POLYACRYLIC ACID; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; SOLID LIPID NANOPARTICLE; DELAYED RELEASE FORMULATION;

AEROSOL; CONTROLLED DRUG RELEASE; CONTROLLED PULMONARY DRUG DELIVERY; CONTROLLED RELEASE FORMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRY POWDER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG CLEARANCE; MACROPHAGE; MUCOCILIARY CLEARANCE; PHAGOCYTOSIS; REVIEW; ADMINISTRATION AND DOSAGE; ANIMAL; DELAYED RELEASE FORMULATION; MEDICINAL CHEMISTRY; METABOLISM;

ADMINISTRATION, INHALATION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; POLYMERS;

EID: 84925396725     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.09.020     Document Type: Review

References (96)

1. M. Decramer Chronic obstructive pulmonary disease Lancet 379 2012 1341 1351
2. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 2010 1 19
3. B. Olsson Pulmonary drug metabolism, clearance, and absorption H.D. Smyth, A.J. Hickey, Controlled Pulmonary Drug Delivery 2nd edn 2011 Springer 21 50
4. M. Sanders Pulmonary drug delivery: an historical overview H.D. Smyth, A.J. Hickey, Controlled Pulmonary Drug Delivery 2nd edn 2011 Springer 51 73
5. W. Stahlhofen Short-term and long-term clearance of particles from the upper human respiratory tract as function of particle size J. Aerosol Sci. 21 1990 S407 S410
6. G. Oberdörster Lung clearance of inhaled insoluble and soluble particles J. Aerosol Med. 1 1988 289 330
7. P. Sheth, and P.B. Myrdal Polymers for pulmonary drug delivery H.D. Smyth, A.J. Hickey, Controlled Pulmonary Drug Delivery 2nd edn 2011 Springer 265 282
8. M.D. Louey, and L. Garcia-Contreras Controlled release products for respiratory delivery Am. Pharm. Rev. 7 2004 82 87
9. H. Takeuchi Mucoadhesive nanoparticulate systems for peptide drug delivery Adv. Drug Deliv. Rev. 47 2001 39 54
10. H. Yamamoto Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions J. Control. Release 102 2005 373 381
11. M. Murata Pulmonary delivery of elcatonin using surface-modified liposomes to improve systemic absorption: polyvinyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective surface modifiers Eur. J. Pharm. Biopharm. 80 2012 340 346
12. H.Y. Li, and J. Birchall Chitosan-modified dry powder formulations for pulmonary gene delivery Pharm. Res. 23 2006 941 950
13. P.S. Pourshahab Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid J. Microencapsul. 28 2011 605 613
14. A. Makhlof Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin Int. J. Pharm. 397 2010 92 95
15. X. Xu Synthesis, in vitro and in vivo evaluation of new norcantharidin-conjugated hydroxypropyltrimethyl ammonium chloride chitosan derivatives as polymer therapeutics Int. J. Pharm. 453 2013 610 619
16. L. Allegra Hyaluronic acid: perspectives in lung diseases Handb. Exp. Pharmacol. 207 2012 385 401
17. K.I. Morimoto Effects of low-viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats Drug Dev. Ind. Pharm. 27 2001 365 371
18. J.J. Rouse Controlled drug delivery to the lung: influence of hyaluronic acid solution conformation on its adsorption to hydrophobic drug particles Int. J. Pharm. 330 2007 175 182
19. K. Surendrakumar Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs J. Control. Release 91 2003 385 394
20. C. Wischke, and S.P. Schwendeman Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles Int. J. Pharm. 364 2008 298 327
21. F. Ungaro Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises J. Pharm. Pharmacol. 64 2012 1217 1235
22. E. Rytting Biodegradable polymeric nanocarriers for pulmonary drug delivery Expert Opin. Drug Deliv. 5 2008 629 639
23. M. Beck-Broichsitter Controlled pulmonary drug and gene delivery using polymeric nano-carriers J. Control. Release 161 2012 214 224
24. L.A. Dailey The role of branched polyesters and their modifications in the development of modern drug delivery vehicles J. Control. Release 101 2005 137 149
25. L.A. Dailey, and T. Kissel New poly(lactic-co-glycolic acid) derivatives: modular polymers with tailored properties Drug Discov. Today: Technol. 2 2005 7 13
26. B. Devrim Preparation and evaluation of PLGA microparticles as carrier for the pulmonary delivery of rhIL-2: I. Effects of some formulation parameters on microparticle characteristics J. Microencapsul. 28 2011 582 594
27. T.V.P. Doan Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery Int. J. Pharm. 414 2011 112 117
28. J. He Sustained release of low molecular weight heparin from PLGA microspheres prepared by a solid-in-oil-in-water emulsion method J. Microencapsul. 28 2011 763 770
29. J. He Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer Int. J. Pharm. 416 2011 69 76
30. A. Yildiz Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation J. Control. Release 162 2012 456 463
31. F. Tewes Evaluation of HP beta CD-PEG microparticles for salmon calcitonin administration via pulmonary delivery Mol. Pharm. 8 2011 1887 1898
32. H. Tawfeek Poly(glycerol adipate-co-omega-pentadecalactone) spray-dried microparticles as sustained release carriers for pulmonary delivery Pharm. Res. 28 2011 2086 2097
33. M. Vijayaraghavan Suitability of polymer materials for production of pulmonary microparticles using a PGSS supercritical fluid technique: thermodynamic behaviour of fatty acids, PEGs and PEG-fatty acids Int. J. Pharm. 438 2012 225 231
34. P. Begat The cohesive-adhesive balances in dry powder inhaler formulations I: direct quantification by atomic force microscopy Pharm. Res. 21 2004 1591 1597
35. D.A. Edwards Large porous particles for pulmonary drug delivery Science 276 1997 1868 1872
36. I. Kim Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer Biomaterials 33 2012 5574 5583
37. I. Kim Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer Biomaterials 34 2013 6444 6453
38. M.M. Arnold NanoCipro encapsulation in monodisperse large porous PLGA microparticles J. Control. Release 121 2007 100 109
39. A.-Z. Chen Preparation of methotrexate-loaded, large, highly-porous PLLA microspheres by a high-voltage electrostatic antisolvent process J. Mater. Sci. Mater. Med. 24 2013 1917 1925
40. A.-Z. Chen Generation of porous poly-l-lactide microspheres by emulsion-combined precipitation with a compressed CO2 antisolvent process J. Mater. Chem. B 1 2013 2967 2975
41. K. Koushik, and U.B. Kompella Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process Pharm. Res. 21 2004 524 535
42. K. Koushik Pulmonary delivery of deslorelin: large-porous PLGA particles and HP beta CD complexes Pharm. Res. 21 2004 1119 1126
43. D.S. Dhanda Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose J. Control. Release 168 2013 239 250
44. H.K. Kim Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone J. Control. Release 112 2006 167 174
45. W. Rojanarat Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies Int. J. Mol. Sci. 12 2011 4414 4434
46. V. Gupta PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-beta-cyclodextrin (PGE1-HPbetaCD) complex for the treatment of pulmonary arterial hypertension (PAH) Pharm. Res. 28 2011 1733 1749
47. K. Mobus Zinc-alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying Eur. J. Pharm. Biopharm. 81 2012 121 130
48. I.M. El-Sherbinyl Swelling characteristics and in vitro drug release study with pH- and thermally sensitive hydrogels based on modified chitosan J. Appl. Polym. Sci. 102 2006 977 985
49. I.M. El-Sherbiny Swellable microparticles as carriers for sustained pulmonary drug delivery J. Pharm. Sci. 99 2010 2343 2356
50. I.M. El-Sherbiny, and H.D.C. Smyth Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres Int. J. Pharm. 395 2010 132 141
51. I.M. El-Sherbiny, and H.D.C. Smyth Novel cryomilled physically cross-linked biodegradable hydrogel microparticles as carriers for inhalation therapy J. Microencapsul. 27 2010 657 668
52. I.M. El-Sherbiny, and H.D.C. Smyth Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles Mol. Pharm. 9 2012 269 280
53. J.C. Sung Nanoparticles for drug delivery to the lungs Trends Biotechnol. 25 2007 563 570
54. H.M. Mansour Nanomedicine in pulmonary delivery Int. J. Nanomed. 4 2009 299 319
55. L.A. Dailey Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features J. Control. Release 86 2003 131 144
56. M. Beck-Broichsitter Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb (R) Pro: formulation aspects and nanoparticle stability to nebulization Int. J. Pharm. 422 2012 398 408
57. F.A. Oyarzun-Ampuero Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma Int. J. Pharm. 381 2009 122 129
58. A.B. Watts, and R.O.I. Williams Nanoparticles for pulmonary delivery H.D. Smyth, A.J. Hickey, Controlled Pulmonary Drug Delivery 2nd edn 2011 Springer 335 366
59. P.G.A. Rogueda, and D. Traini The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects Expert Opin. Drug Deliv. 4 2007 595 606
60. P.G.A. Rogueda, and D. Traini The nanoscale in pulmonary delivery. Part 2: formulation platforms Expert Opin. Drug Deliv. 4 2007 607 620
61. S. Azarmi Targeted delivery of nanoparticles for the treatment of lung diseases Adv. Drug Deliv. Rev. 60 2008 863 875
62. W. Yang Inhaled nanoparticles - a current review Int. J. Pharm. 356 2008 239 247
63. C.Y. Dombu, and D. Betbeder Airway delivery of peptides and proteins using nanoparticles Biomaterials 34 2013 516 525
64. A.S. Ulrich Biophysical aspects of using liposomes as delivery vehicles Biosci. Rep. 22 2002 129 150
65. J. Swaminathan, and C. Ehrhardt Liposomes for pulmonary drug delivery H.D. Smyth, A.J. Hickey, Controlled Pulmonary Drug Delivery 2nd edn 2011 Springer 313 334
66. J. Swaminathan, and C. Ehrhardt Liposomal delivery of proteins and peptides Expert Opin. Drug Deliv. 9 2012 1489 1503
67. A. Misra Recent advances in liposomal dry powder formulations: preparation and evaluation Expert Opin. Drug Deliv. 6 2009 71 89
68. L.-J. Zhang Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes Pulm. Pharmacol. Ther. 21 2008 239 246
69. P.T. Ingvarsson Stabilization of liposomes during drying Expert Opin. Drug Deliv. 8 2011 375 388
70. C. Chen An overview of liposome lyophilization and its future potential J. Control. Release 142 2010 299 311
71. M. Murata Surface modification of liposomes using polymer-wheat germ agglutinin conjugates to improve the absorption of peptide drugs by pulmonary administration J. Pharm. Sci. 102 2013 1281 1289
72. C. Jaafar-Maalej Lipid-based carriers: manufacturing and applications for pulmonary route Expert Opin. Drug Deliv. 9 2012 1111 1127
73. J. Liu Solid lipid nanoparticles for pulmonary delivery of insulin Int. J. Pharm. 356 2008 333 344
74. X. Yang Biodegradable solid lipid nanoparticle flocculates for pulmonary delivery of insulin J. Biomed. Nanotechnol. 8 2012 834 842
75. N. Tsapis Trojan particles: large porous carriers of nanoparticles for drug delivery Proc. Natl. Acad. Sci. U. S. A. 99 2002 12001 12005
76. K. Hadinoto Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery Int. J. Pharm. 341 2007 195 206
77. A. Grenha Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins Eur. J. Pharm. Biopharm. 69 2008 83 93
78. J.C. Sung Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery Pharm. Res. 26 2009 1847 1855
79. W.S. Cheow Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants Int. J. Pharm. 404 2011 289 300
80. L. Yang Development of a pulmonary peptide delivery system using porous nanoparticle-aggregate particles for systemic application Int. J. Pharm. 451 2013 104 111
81. J. Lee Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery J. Control. Release 146 2010 61 67
82. A. Rawat Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation J. Control. Release 128 2008 224 232
83. V. Gupta, and F. Ahsan Influence of PEI as a core modifying agent on PLGA microspheres of PGE(1), a pulmonary selective vasodilator Int. J. Pharm. 413 2011 51 62
84. Y. Yang Development of highly porous large PLGA microparticles for pulmonary drug delivery Biomaterials 30 2009 1947 1953
85. F. Ungaro Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung Eur. J. Pharm. Sci. 41 2010 60 70
86. D. De Stefano Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-kappa B delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells J. Gene Med. 13 2011 200 208
87. W. Wong Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems J. Pharm. Sci. 100 2011 4710 4721
88. N.Y. Yoo Antioxidant encapsulated porous poly(lactide-co-glycolide) microparticles for developing long acting inhalation system Colloids Surf. B Biointerfaces 88 2011 419 424
89. M.J. Kwona Long acting porous microparticle for pulmonary protein delivery Int. J. Pharm. 333 2007 5 9
90. E.S. Lee Protein release behavior from porous microparticle with lysozyme/hyaluronate ionic complex Colloids Surf. B Biointerfaces 55 2007 125 130
91. F. Ungaro Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs Eur. J. Pharm. Sci. 28 2006 423 432
92. F. Ungaro Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs J. Control. Release 135 2009 25 34
93. H. Kim Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes Pharm. Res. 28 2011 2008 2019
94. M. Nasr Hydrophilic versus hydrophobic porogens for engineering of poly(lactide-co-glycolide) microparticles containing risedronate sodium Pharm. Dev. Technol. 18 2013 1078 1088
95. B. Patel PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin J. Control. Release 162 2012 310 320
96. K. Kho Aqueous re-dispersibility of spray-dried antibiotic-loaded polycaprolactone nanoparticle aggregates for inhaled anti-biofilm therapy Powder Technol. 203 2010 432 439